Allianz warns nuclear verdicts have almost trebled since 2020

Published: Wed 20 Nov 2024

Pharma class actions, mounting PFAS litigation and the growth of collective redress outside the US are creating a challenging market for liability insurers, which are already grappling with “spiralling” claims costs as nuclear verdicts increase in number and size, according to Allianz Commercial.